Logo

Lilly Files Lasmiditan to FDA for Acute Treatment of Migrane

Share this
Lilly Files Lasmiditan to FDA for Acute Treatment of Migrane

Lilly Files Lasmiditan to FDA for Acute Treatment of Migrane

Shots: •      The NDA filling is based on results of P-III SAMURAI and SPARTAN study assessing Lasmiditan vs PBO in patients with migrane with or without aura in adults •     The collective results of the study demonstrated safety and efficacy of Lasmiditan- meeting all 1EP & 2EP- showing greater percentage of patients free of their most bothersome symptom (MBS) •      Lasmiditan is a selective serotonin 5-HT1F agonist and is developed for acute treatment of migrane in adults Ref: Eli Lilly | Image: Wall Street Journal

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions